Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for KYTH
-1.08 (-3.10%)
Real-time:   3:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.48 - 34.71
52 week 23.03 - 56.36
Open 34.30
Vol / Avg. 99,597.00/210,582.00
Mkt cap 764.91M
P/E     -
Div/yield     -
EPS -5.12
Shares 22.66M
Beta     -
Inst. own 109%
Aug 4, 2014
Q2 2014 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jun 12, 2014
KYTHERA Biopharmaceuticals Inc at Goldman Sachs Healthcare Conference
May 14, 2014
Kythera Biopharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Q1 2014 Kythera Biopharmaceuticals Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Kythera Biopharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -169.30% -38.51%
Return on average equity -209.70% -47.46%
Employees 64 -
CDP Score - -


Suite 200 27200 West Agoura Road
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is a injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted, ATX-101 has exhibited results in the reduction of submental fat. ATX-101 contains a synthetic form of sodium deoxycholate. In the United States and Canada, the Company is conducting two pivotal Phase III trials of ATX-101 for the reduction of submental fat. The Company initiated this pivotal Phase III clinical program, with planned enrollment of 1,000 patients, in March 2012.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Jeffrey D. Webster Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel
Age: 50
Bio & Compensation  - Reuters
Frederick Beddingfield III, M.D., Ph.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 58
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 47
Bio & Compensation  - Reuters
Robert T. Nelsen Independent Director
Age: 50
Bio & Compensation  - Reuters